LIFR (Leukaemia inhibitory factor receptor) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma and Small-cell lung cancer. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Functions as a membrane-bound signal-transducing subunit either in complex with IL6ST/gp130 or as part of the ciliary neurotrophic factor receptor (CNTFR) complex composed by CNTFR, IL6ST/gp130 and LIFR. Signal transmission is initiated either by binding directly to cytokines, such as OSM or LIF or CTF1, or through the binding of other cytokines, like CNTF, CLCF1 or the heterodimeric complex CRLF1-CLCF1 to the non-signalling receptor CNTFR; ligand binding induces heterodimerisation of IL6ST/gp130 and LIFR which activates JAK tyrosine kinases bound to their intracellular domains. These kinases subsequently phosphorylate the homodimer or heterodimer form of IL6ST/gp130. The tyrosine phosphorylated signalling receptors serve in turn as docking sites for recruitment and activation of signal transducer and activators of transcription (STATs). Engages sites 3 of ligands cytokines. Could inhibit the biological activity of LIF by blocking its binding to receptors on target cells. Location: Cell membrane; Secreted (UniProt). Locus 5p13.1 (HGNC).
- Melanoma: IntOGen driver in 1 cohort (MEL)
- Small-cell lung cancer: IntOGen driver in 1 cohort (SCLC)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"LIFR" OR ABSTRACT:"LIFR" OR TITLE:"LIF receptor subunit alpha" OR ABSTRACT:"LIF receptor subunit alpha" OR TITLE:"Leukemia inhibitory factor receptor" OR ABSTRACT:"Leukemia inhibitory factor receptor" OR TITLE:"CD118" OR ABSTRACT:"CD118") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LIFR, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/lifr.json. Licence CC BY-NC 4.0.